Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 6/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20125088 | 0.80 | CYP1A2 (0.49) | POLBCYP1A2CYP2C9TGFBR1 | |
| SCHEMBL17812869 | 0.78 | POLB (0.64) | POLBDGAT1MEN1KMT2ACYP1A2 | |
| SCHEMBL2259799 | 0.77 | POLB (0.37) | POLBCLK1RXRATGFBR1 | |
| SCHEMBL23775720 | 0.73 | KDM4E (0.38) | POLBCLK1DGAT1RXRACYP1A2 | |
| SCHEMBL13976120 | 0.73 | LMNA (0.39) | POLBCLK1DGAT1EGLN1RXRA | |
| SCHEMBL22521532 | 0.73 | TGFBR1 (0.41) | POLBCLK1DGAT1RXRAEIF2AK4 | |
| SCHEMBL23872984 | 0.72 | TGFBR1 (0.47) | DGAT1CYP1A2CYP2C9TGFBR1 | |
| SCHEMBL22944713 | 0.71 | NPC1 (0.35) | POLBCLK1DGAT1CYP1A2CYP2C9 | |
| SCHEMBL23511269 | 0.71 | DGAT1 (0.40) | POLBCLK1DGAT1EGLN1CYP1A2 | |
| SCHEMBL20801795 | 0.71 | TYR (0.39) | CLK1DGAT1EGLN1RXRAEIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | POLB 1124/4885CLK1 1596/4885DGAT1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.